Survival outcomes and tumor IMP3 expression in patients with sarcomatoid metastatic renal cell carcinoma

noticia |

Tantravahi S.K., Albertson D., Agarwal A.M., Ravulapati S., Poole A., Patel S.B., Hawatmeh J.S., Straubhar A.M., Liu T., Stenehjem D.D., Agarwal N.

Journal of Oncology 2015 2015 Article Number 181926

Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients from a single institutional database. To identify predictive and prognostic biomarkers, immunohistochemistry (IHC) analysis was performed on the tumor samples for downstream targets of VEGF and mTOR pathways. Survival outcomes were stratified by IHC analysis, extent of sarcomatoid component, Memorial Sloan-Kettering Cancer Center (MSKCC), and Heng risk criteria. Twenty-seven patients with SmRCC were included. First line therapy included targeted therapy (n = 19), immunotherapy (n = 4), cytotoxic chemotherapy (n = 1), and no treatment (n = 3). Median OS was…(vermás)


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)